The European Medicines Agency�s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Teva Pharmaceuticals Industries� $TEVA Trisenox (arsenic trioxide) for the treatment of newly diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL), an uncommon type of acute myeloid leukemia that can rapidly be life-threatening due to intense bleeding. Every year, about 1,500-2000 Europeans suffer from this complication. The treatment was first approved in the EU in March 2002 for the treatment of relapsed/refractory APL. In the U.S. it got approved in 2000. Typically, it takes about 60 days to make a final decision by the European Commission.